Normand E. Allaire
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Normand E. Allaire has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Graham J. Brock
Biogen Idec Inc., Genetics and Genomics Group, 14 Cambridge Center, Cambridge, MA 02142, USA
1 shared publication Jadwiga Bienkowska
Biogen Idec, Inc., 14 Cambridge Center, Cambridge, MA 02142, USA
1 shared publication- Jadwiga Bienkowska
Biogen Idec Inc., Genetics and Genomics Group, 14 Cambridge Center, Cambridge, MA 02142, USA
1 shared publication - John P. Carulli
Biogen Idec, Inc., 14 Cambridge Center, Cambridge, MA 02142, USA
1 shared publication - John P. Carulli
Division of Genetics and Genomics, Biogen Idec, 12 Cambridge Center, Cambridge, MA 02142, USA
1 shared publication - Leila Elizabeth Rieder
Department of Biology, Emory University, Atlanta, USA
1 shared publication
Latest Publications
- Open Access
- 5 January 2013
- Published by Springer Nature in BMC Research Notes
- Vol. 6 (1) , 8
Optimization of a high-throughput whole blood expression profiling methodology and its application to assess the pharmacodynamics of interferon (IFN) beta-1a or polyethylene glycol-conjugated IFN beta-1a in healthy clinical trial subjects
Clinical trials offer a unique opportunity to study human disease and response to therapy in a highly controlled setting. The application of high-throughput expression profiling to peripheral blood from clinical trial subjects could facilitate the identification of transcripts that function as prognostic or diagnostic markers of disease or treatment. The paramount issue for these methods is the ability to produce robust, reproducible, and timely mRNA expression profiles from peripheral blood. Single-stranded complementary DNA (sscDNA) targets derived from whole blood exhibit improved detection of transcripts and reduced variance as compared to their complementary RNA counterparts and therefore provide a better option for interrogation of peripheral blood on oligonucleotide arrays. High-throughput microarray technologies such as the high-throughput plate array platform offer several advantages compared with slide- or cartridge-based arrays; however, manufacturer’s protocols do not support the use of sscDNA targets.
- 5 January 2013
- Published by Springer Nature in BMC Research Notes
- Vol. 6 (1) , 8
Open AccessOptimization of a high-throughput whole blood expression profiling methodology and its application to assess the pharmacodynamics of interferon (IFN) beta-1a or polyethylene glycol-conjugated IFN beta-1a in healthy clinical trial subjects
Clinical trials offer a unique opportunity to study human disease and response to therapy in a highly controlled setting. The application of high-throughput expression profiling to peripheral blood from clinical trial subjects could facilitate the identification of transcripts that function as prognostic or diagnostic markers of disease or treatment. The paramount issue for these methods is the ability to produce robust, reproducible, and timely mRNA expression profiles from peripheral blood. Single-stranded complementary DNA (sscDNA) targets derived from whole blood exhibit improved detection of transcripts and reduced variance as compared to their complementary RNA counterparts and therefore provide a better option for interrogation of peripheral blood on oligonucleotide arrays. High-throughput microarray technologies such as the high-throughput plate array platform offer several advantages compared with slide- or cartridge-based arrays; however, manufacturer’s protocols do not support the use of sscDNA targets.